Latest SIMPONI Stories

2009-10-06 10:14:00

HORSHAM, Pa. and KENILWORTH, N.J., Oct. 6 /PRNewswire/ -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS). In the European Union, SIMPONI is approved as a 50 mg subcutaneous...

2009-05-08 14:02:00

EXTON, Pa., May 8 /PRNewswire/ -- BioTrends Research Group released highlights from its baseline wave of LaunchTrends(TM): SIMPONI, a four wave syndicated research study that will track uptake of the drug from FDA approval through six months post launch. The research is based on results of a survey of 77 Rheumatologists conducted on-line between May 5th and May 7th. 95% of the Rheumatologists surveyed were aware of SIMPONI and about one-third had been called on by SIMPONI sales...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.